Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 9 | 2023 | 540 | 2.520 |
Why?
|
| Neoplasms | 4 | 2025 | 809 | 1.840 |
Why?
|
| Cachexia | 3 | 2024 | 53 | 1.760 |
Why?
|
| Stomach Neoplasms | 3 | 2025 | 25 | 1.090 |
Why?
|
| Immunotherapy | 2 | 2025 | 161 | 1.000 |
Why?
|
| Biomarkers, Tumor | 2 | 2025 | 405 | 0.910 |
Why?
|
| Acetate-CoA Ligase | 1 | 2022 | 9 | 0.780 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 1461 | 0.780 |
Why?
|
| BRCA2 Protein | 1 | 2021 | 19 | 0.720 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 24 | 0.710 |
Why?
|
| Cell Line, Tumor | 11 | 2025 | 1319 | 0.710 |
Why?
|
| Exosomes | 1 | 2023 | 96 | 0.710 |
Why?
|
| Adenosine | 1 | 2021 | 33 | 0.700 |
Why?
|
| Signal Transduction | 7 | 2025 | 1435 | 0.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 409 | 0.630 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2019 | 6 | 0.630 |
Why?
|
| Cell Communication | 1 | 2019 | 68 | 0.590 |
Why?
|
| Cation Transport Proteins | 4 | 2025 | 60 | 0.560 |
Why?
|
| Mice | 12 | 2025 | 4654 | 0.510 |
Why?
|
| Prognosis | 3 | 2025 | 803 | 0.510 |
Why?
|
| Macrophages | 1 | 2019 | 295 | 0.500 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 459 | 0.490 |
Why?
|
| Humans | 17 | 2025 | 28097 | 0.480 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 3 | 2021 | 26 | 0.480 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2025 | 42 | 0.430 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2025 | 115 | 0.430 |
Why?
|
| Cell Movement | 5 | 2025 | 373 | 0.430 |
Why?
|
| STAT3 Transcription Factor | 4 | 2025 | 97 | 0.420 |
Why?
|
| Tumor Microenvironment | 3 | 2025 | 178 | 0.410 |
Why?
|
| Animals | 12 | 2025 | 10423 | 0.380 |
Why?
|
| Neoplasm Metastasis | 4 | 2025 | 162 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2025 | 465 | 0.250 |
Why?
|
| Receptor, Notch1 | 1 | 2025 | 27 | 0.240 |
Why?
|
| Myosin Heavy Chains | 1 | 2025 | 24 | 0.240 |
Why?
|
| Muscles | 2 | 2022 | 73 | 0.240 |
Why?
|
| beta Catenin | 1 | 2025 | 66 | 0.230 |
Why?
|
| DNA Helicases | 1 | 2025 | 52 | 0.230 |
Why?
|
| Wnt Signaling Pathway | 1 | 2025 | 57 | 0.230 |
Why?
|
| Microglia | 1 | 2025 | 64 | 0.230 |
Why?
|
| Extracellular Vesicles | 1 | 2025 | 43 | 0.230 |
Why?
|
| Zinc | 2 | 2025 | 63 | 0.230 |
Why?
|
| Female | 5 | 2025 | 15156 | 0.230 |
Why?
|
| Nerve Tissue Proteins | 1 | 2025 | 153 | 0.220 |
Why?
|
| Disease Progression | 3 | 2025 | 473 | 0.220 |
Why?
|
| Neoplastic Stem Cells | 1 | 2025 | 141 | 0.220 |
Why?
|
| Glioblastoma | 1 | 2025 | 105 | 0.220 |
Why?
|
| Integrin alpha3 | 2 | 2021 | 18 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 29 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 73 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 167 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2025 | 269 | 0.200 |
Why?
|
| Lysosomes | 1 | 2023 | 56 | 0.200 |
Why?
|
| Dynamin II | 1 | 2022 | 13 | 0.200 |
Why?
|
| Tumor Necrosis Factors | 1 | 2022 | 15 | 0.200 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 21 | 0.200 |
Why?
|
| Dextrans | 1 | 2022 | 23 | 0.200 |
Why?
|
| Syndecan-1 | 1 | 2022 | 13 | 0.200 |
Why?
|
| Models, Biological | 3 | 2021 | 466 | 0.200 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 300 | 0.190 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2022 | 39 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 301 | 0.190 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2021 | 6 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2021 | 8 | 0.180 |
Why?
|
| Membrane Proteins | 1 | 2025 | 484 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 109 | 0.180 |
Why?
|
| Cell Proliferation | 5 | 2025 | 806 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 79 | 0.180 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 38 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2022 | 76 | 0.180 |
Why?
|
| Dexamethasone | 1 | 2021 | 63 | 0.180 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 36 | 0.180 |
Why?
|
| Cell Plasticity | 1 | 2021 | 10 | 0.180 |
Why?
|
| Lipids | 1 | 2022 | 208 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 155 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2022 | 301 | 0.180 |
Why?
|
| Area Under Curve | 1 | 2021 | 95 | 0.180 |
Why?
|
| Tumor Burden | 1 | 2021 | 110 | 0.180 |
Why?
|
| ROC Curve | 1 | 2021 | 144 | 0.170 |
Why?
|
| Male | 4 | 2025 | 13491 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 135 | 0.170 |
Why?
|
| Prostaglandin D2 | 1 | 2020 | 6 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 194 | 0.170 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 478 | 0.170 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 226 | 0.170 |
Why?
|
| Proteomics | 1 | 2022 | 181 | 0.170 |
Why?
|
| Survival Analysis | 1 | 2021 | 288 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 148 | 0.170 |
Why?
|
| Integrin beta1 | 1 | 2019 | 15 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2021 | 253 | 0.160 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 634 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 48 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 163 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2019 | 65 | 0.160 |
Why?
|
| Chemokine CXCL5 | 1 | 2019 | 7 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 452 | 0.160 |
Why?
|
| Chemokine CXCL1 | 1 | 2019 | 7 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 138 | 0.160 |
Why?
|
| Coculture Techniques | 1 | 2019 | 55 | 0.150 |
Why?
|
| Treatment Outcome | 1 | 2025 | 2379 | 0.150 |
Why?
|
| Cohort Studies | 1 | 2021 | 887 | 0.150 |
Why?
|
| Claudin-1 | 1 | 2018 | 7 | 0.150 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2018 | 17 | 0.150 |
Why?
|
| Mutation | 1 | 2021 | 847 | 0.140 |
Why?
|
| Gene Expression | 1 | 2019 | 417 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2021 | 520 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 298 | 0.130 |
Why?
|
| Middle Aged | 2 | 2025 | 7138 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2025 | 190 | 0.100 |
Why?
|
| Mice, Nude | 2 | 2025 | 331 | 0.090 |
Why?
|
| Spheroids, Cellular | 2 | 2021 | 53 | 0.080 |
Why?
|
| Heterografts | 2 | 2021 | 66 | 0.080 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2025 | 6 | 0.060 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2025 | 13 | 0.060 |
Why?
|
| Proteolysis | 1 | 2025 | 58 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2025 | 276 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2022 | 38 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 15 | 0.050 |
Why?
|
| Databases, Genetic | 1 | 2021 | 48 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 59 | 0.040 |
Why?
|
| Protein Transport | 1 | 2021 | 158 | 0.040 |
Why?
|
| Pancreas | 1 | 2020 | 61 | 0.040 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2019 | 15 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2019 | 58 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 90 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 120 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 658 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 134 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 453 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 179 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 430 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2019 | 578 | 0.040 |
Why?
|
| Apoptosis | 1 | 2021 | 775 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 463 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 403 | 0.030 |
Why?
|